Direct compression of meprednisone hemisuccinate into immediate-release tablets requires a starting particle size distribution where not more than 15% w/w of the API fraction is retained on a 0.250 mm sieve; this is measured by analytical sieving under Ph. Eur. 2.9.38 or USP <786>. In a low-dose oral solid intended for a 100 mg core, a preliminary formulation of 4.0% w/w meprednisone hemisuccinate, 68.0% w/w mannitol, 22.5% w/w microcrystalline cellulose, 4.0% w/w crospovidone, 0.5% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate is screened. The blend is prepared by geometric dilution in a 200 L bin blender at 12 rpm for 15 min, followed by lubricant addition and an additional 3 min blend; content uniformity is then tested under USP <905> using ten tablets with an acceptance value not exceeding 15. Compression on a rotary tablet press fitted with 8 mm round biconcave tooling commonly requires a main compression force between 6 kN and 12 kN; hardness is held at 60–100 N and friability is kept below 1.0% w/w according to Ph. Eur. 2.9.7 or USP <1216>. Disintegration is tested in 900 mL of 0.1 M hydrochloric acid at 37 °C using Ph. Eur. 2.9.1; the acceptance criterion is complete disintegration within 15 min. Because the hemisuccinate ester is susceptible to pH-dependent hydrolysis, direct compression is preferred over aqueous wet granulation; if aqueous granulation is unavoidable, the binder solution hold time should be limited to 2 h at 20–25 °C and the wet mass must be dried to a final loss on drying not exceeding 2.0% w/w under Ph. Eur. 2.5.12. The terminal product is a film-coated immediate-release tablet, with coating applied in a perforated pan at 38–42 °C inlet air temperature to avoid heat-induced degradation of the hemisuccinate group.

What Limits Direct Encapsulation Uniformity Below 2% w/w API Loading?

Direct filling of meprednisone hemisuccinate into hard gelatin or HPMC capsules becomes process-sensitive when the active content falls below 2.0% w/w. At that dilution, fines migration during hopper discharge creates superpotent samples near the end of the batch. A two-stage mixing sequence using a 50 L V-blender or bin blender is therefore required: the API is first geometric pre-blended with a fine carrier such as micronized lactose or spray-dried mannitol at a 1:4 ratio for 10 min, then passed through a 0.500 mm sieve, and finally diluted with the remaining filler and disintegrant. A possible capsule formulation for a 1 mg strength in a size 3 capsule is 1.0% w/w API, 83.5% w/w lactose monohydrate, 12.0% w/w pregelatinized starch, 2.5% w/w croscarmellose sodium, and 1.0% w/w sodium stearyl fumarate. The final blend is discharged into a dosator-type capsule filling machine; automated checkweighing of empty and filled capsules at intervals not exceeding 15 min is used to detect powder bed segregation before it produces weight variation outside ±5% of target fill weight. Dissolution testing under USP <711> uses apparatus 2 at 50 rpm, 900 mL of 0.1 M hydrochloric acid, and a sinker to prevent capsule floating; sampling at 15 min, 30 min, and 45 min is compared against the immediate-release acceptance criterion of Q=80% in 30 min. Because the capsule shell introduces moisture and gelatin can interact with trace aldehydes, HPMC shells are preferred for stability when the API is stored above 25 °C or when the finished product is destined for zone IVb countries. The terminal product is typically a size 3 immediate-release capsule with an opaque body to protect the hemisuccinate from light.

Granules for oral suspension are manufactured by fluid-bed top-spray granulation in a Wurster-type fluid bed when the meprednisone hemisuccinate content is below 5.0% w/w. The binding solution, typically 5% w/w povidone K30 or a pregelatinized starch dispersion, is sprayed onto a fluidized blend of mannitol and microcrystalline cellulose. Because the hemisuccinate ester undergoes hydrolysis in the presence of free moisture, the product temperature is kept below 40 °C during spray granulation and the atomizing air is maintained at a dew point below -20 °C. Final granule moisture is measured by coulometric Karl Fischer titration under Ph. Eur. 2.5.12; the release limit is not more than 1.5% w/w. Sieve analysis under Ph. Eur. 2.9.38 requires not less than 90% w/w of granules to pass through a 1.000 mm sieve and not more than 30% w/w to pass through a 0.150 mm sieve, thereby limiting both sticking and segregation. A typical sachet formulation contains 2.5% w/w API, 70.0% w/w sucrose or sorbitol, 15.0% w/w dextrose, 5.0% w/w povidone, 1.0% w/w sodium citrate, 0.2% w/w sodium benzoate, and flavoring agents; the powder is filled into paper/aluminum/polyethylene sachets at a fill weight of 2.000 g. Reconstituted suspension stability is evaluated at 2–8 °C for 7 days with pH monitored between 4.5 and 6.0. The terminal product is a dry granule for oral suspension that is reconstituted with 10 mL of purified water immediately before administration; a marked oral dosing spoon or syringe is supplied to reduce dosing error in pediatric patients.

Lyophilized Injectable Presentation and Residual Moisture Control

Meprednisone hemisuccinate as a pharma-grade API is suited to a lyophilized powder for injection because the hemisuccinate salt provides water solubility for reconstitution while the freeze-dried cake limits hydrolytic degradation during shelf storage. A documented formulation for a 50 mg/vial presentation comprises the API as meprednisone hemisuccinate equivalent to 50 mg meprednisone, 200 mg mannitol, 10 mg monobasic sodium phosphate dihydrate, and sodium hydroxide for pH adjustment to 6.5–7.5. The bulk solution is compounded in a 316L stainless steel tank under nitrogen overlay at 20–25 °C and filtered through a 0.22 µm PVDF membrane prior to filling into 10 mL Type I borosilicate glass vials. Lyophilization is performed in a freeze dryer with a shelf capacity of 20 m²; the thermal cycle includes freezing to -45 °C at a ramp rate of 0.5 °C/min, primary drying at -20 °C and chamber pressure of 100 µbar for 18 h, and secondary drying at 25 °C for 8 h. Residual moisture is measured by coulometric Karl Fischer and release limited to not more than 1.0% w/w; headspace oxygen is controlled below 1.0% v/v by vacuum-stoppering under nitrogen. The lyophilized cake must meet payload sterility under USP <71>, bacterial endotoxin under USP <85>, sub-visible particulates under USP <788> or Ph. Eur. 2.9.19, and visible particulates under USP <790>. Batch release includes reconstitution time not exceeding 2 min with 5 mL of sterile water for injection, yielding a clear to slightly opalescent solution with pH 6.5–7.5. Because residual moisture and ester hydrolysis are directly linked, the freeze-dried vial is stored below 25 °C and protected from light; the single-dose vial is intended for immediate use after reconstitution and is not preserved for multiple withdrawal.

When Terminal Sterilization Is Not Feasible for the Hemisuccinate Solution

A ready-to-use injectable solution of meprednisone hemisuccinate is generally not a candidate for saturated-steam terminal sterilization because the hemisuccinate ester is vulnerable to hydrolytic cleavage at 121 °C; the degradation rate increases as the solution is held in the liquid state. Under these conditions, aseptic processing is the primary route. The bulk solution is compounded at 20–25 °C in a closed stainless steel vessel and adjusted to pH 6.5–7.0 with sodium hydroxide or hydrochloric acid. The formulation may contain 0.9% w/v sodium chloride or 5.0% w/v dextrose as an iso-osmotic vehicle, together with a buffering system such as 10 mM citrate or phosphate. Filtration through a 0.22 µm validated sterilizing-grade membrane is performed under aseptic conditions; filter integrity is confirmed before and after filtration by bubble point or diffusive flow testing in accordance with ASTM F838-20. Bulk hold time is limited to 8 h at 20–25 °C and 24 h at 2–8 °C to restrict pre-filtration bioburden and post-compounding hydrolysis. The solution is filled into USP Type I glass vials or ampoules under EU GMP Annex 1 Grade A conditions; fill volume is checked according to USP <1151> and particulates are controlled under USP <788>. Sterility testing follows USP <71> using membrane filtration of 20 units per batch, and bacterial endotoxin testing follows USP <85>. The finished ampoule or vial is stored at 2–8 °C, protected from light, and must not be mixed with solutions containing magnesium or calcium salts unless compatibility data are available. The terminal product is a single-dose injectable solution for intravenous or intramuscular administration after visual inspection and leaker testing.